← Back to screener

Neumora Therapeutics, Inc. NMRA

Rank #1658 · Nasdaq · $0.1B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
44.8
P/E
-0.3
P/B
0.15
ROE
-52.0%
Op. Margin
–%
Debt Ratio
6%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -0.3x, P/B 0.15x. Ranks in the top 50% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -52.0%. Ranks in the top 89% of the universe.

Safety ★★★★★
Excellent

Debt ratio 6%. Ranks in the top 9% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2023–$-0.1B$-0.1B$-0.3B–-9
2024–$-0.1B$-0.1B$-0.3B–-8
2025–$-0.3B$-0.2B$0.5B–6

← See the full screener